What one share of Kiora Pharmaceuticals holds
We are developing KIO-301, with an initial focus on patients with later stages of vision loss due to retinitis pigmentosa (collectively including any and all sub-forms, "RP"). KIO-301 is a potential vision-restoring small molecule that acts as a “photoswitch” specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including RP.
Kiora Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.33 |
|---|---|
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$1.82 |
| Cash and investments | $1.60 |
| Book value | $3.81 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.95 | −$538.00 | $1.57 | −$575.28 | — | $630.39 |
| 2021 | $0.00 | −$514.05 | $2.38 | −$400.89 | — | $414.44 |
| 2022 | — | −$166.94 | $0.00 | −$128.16 | — | — |
| 2023 | $0.00 | −$24.25 | $0.00 | −$17.76 | — | $7.14 |
| 2024 | $3.88 | $0.87 | $0.00 | $2.07 | — | $8.58 |
| 2025 | $0.00 | −$2.64 | $0.03 | −$2.45 | — | $4.29 |
Common questions about Kiora Pharmaceuticals
How much does one share of Kiora Pharmaceuticals earn?
Over the last 12 months, Kiora Pharmaceuticals lost $2.33 for each share.
Does Kiora Pharmaceuticals pay a dividend?
Kiora Pharmaceuticals didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Kiora Pharmaceuticals’s book value per share?
Kiora Pharmaceuticals’s book value is $3.81 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Kiora Pharmaceuticals have?
Each share of Kiora Pharmaceuticals has $1.60 of cash and investments, as of June 30, 2026.
What is Kiora Pharmaceuticals’s free cash flow per share?
−$1.82 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Kiora Pharmaceuticals bought back shares?
Kiora Pharmaceuticals’s share count rose about 32077% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.